Page 20 - தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update

Published: May 06, 2021 – BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 – – DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., May 06, 2021 (GLOBE NEWSWIRE) Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2021 and provided an operational update. “As we continue execution toward important milestones in the second half of this year, we are also positioning the company for the next phase of growth. This is highlighted by the recent appointment of Vicki Vakiener who brings extensive commercial and oncology experience to our Board of Directors,” said Mike Sherman, Chief Executive Officer of Chimerix.

United statesVicki vakienerMichelle laspalutoMike shermanChimerix incOncoceutics incBiomedical advanced researchDevelopment authorityEpizyme incExchange commissionIndependent central review expectedSecond halfHigher doseConference callChief executive officerPrescription drug user fee act

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version Lund, Sweden, May 4, 2021. SynAct Pharma AB ( SynAct ) today announced that based upon the encouraging results seen in part 1 of the phase 2 clinical study BEGIN of AP1189, the company has decided to increase the study size in an effort to demonstrate statistical significance in the trial. SynAct Publicerad: 4 maj 2021, 08:00 Topline data from part 1 of the BEGIN study with AP1189 in early rheumatoid arthristis (RA) demonstrated a 66-74% treatment effect for the 50mg and 100mg dose groups respectively (Part 1 primary endpoint attainment of: placebo - 44%, 50mg - 67% and 100mg – 75%, previously reported in November 2020).

San franciscoUnited statesThomas jonassenSynact pharmaAmerican college of rheumatologyData safety monitoring boardAmerican collegeசான் பிரான்சிஸ்கோஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் கல்லூரி ஆஃப் வாத நோய்தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகைஅமெரிக்கன் கல்லூரி

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaRepublic ofSouth africaCity ofUnited kingdomKimberly smithKathleen quinnJeff mclaughlinSimon steelSonya ghobrialMick readeyAudrey abernathyTim foleyJames dodwellKristen neese

Serum Institute to start phase 3 trials of COVID-19 vaccine Covovax by mid-May

Covovax is the second vaccine candidate after Covishield that SII is manufacturing.

United statesUnited kingdomNew delhiAbhijit kadamUnited kingdom enhanced trade partnershipResearch instituteSerum institute of indiaSerum instituteDrugs controller generalData safety monitoring boardIndian expressIndia united kingdom enhanced trade partnershipCovid 19Serum institute of indiaஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.